CA2216741A1 - A novel protein and process for preparing the same - Google Patents
A novel protein and process for preparing the sameInfo
- Publication number
- CA2216741A1 CA2216741A1 CA002216741A CA2216741A CA2216741A1 CA 2216741 A1 CA2216741 A1 CA 2216741A1 CA 002216741 A CA002216741 A CA 002216741A CA 2216741 A CA2216741 A CA 2216741A CA 2216741 A1 CA2216741 A1 CA 2216741A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- dimer
- preparing
- same
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
A protein comprising an amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing and originating in human MP52 and the dimer of this protein. This dimer protein can be obtained by constructing a plasmid containing a DNA wherein a codon encoding methionine is added to the 5' end of a DNA sequence encoding the above-mentioned aminoacid sequence, transforming Escherichia coli by this plasmid, incubating the E. coli transformant, solubilizing and purifying the obtained inclusion body to thereby give a monomer protein, and then renaturing the obtained monomer protein into the dimer followed by purification. This dimer protein is useful in the treatment of cartilage and bone diseases.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9366495 | 1995-04-19 | ||
JP7/93664 | 1995-04-19 | ||
JP7/322403 | 1995-11-17 | ||
JP32240395 | 1995-11-17 | ||
PCT/JP1996/001062 WO1996033215A1 (en) | 1995-04-19 | 1996-04-19 | Novel protein and process for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2216741A1 true CA2216741A1 (en) | 1996-10-24 |
CA2216741C CA2216741C (en) | 2008-01-15 |
Family
ID=26434967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002216741A Expired - Fee Related CA2216741C (en) | 1995-04-19 | 1996-04-19 | A novel protein and process for preparing the same |
Country Status (18)
Country | Link |
---|---|
US (3) | US7235527B2 (en) |
EP (1) | EP0955313B1 (en) |
AT (1) | ATE325131T1 (en) |
AU (1) | AU704515C (en) |
BR (1) | BR9608019A (en) |
CA (1) | CA2216741C (en) |
DE (2) | DE69636728D1 (en) |
DK (1) | DK0955313T3 (en) |
EA (1) | EA000582B1 (en) |
ES (1) | ES2258774T3 (en) |
HU (1) | HU225424B1 (en) |
NO (1) | NO321153B1 (en) |
NZ (1) | NZ305472A (en) |
OA (1) | OA10528A (en) |
PL (1) | PL186518B1 (en) |
PT (1) | PT955313E (en) |
UA (1) | UA46767C2 (en) |
WO (1) | WO1996033215A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070166353A1 (en) * | 1988-04-08 | 2007-07-19 | Stryker Corporation | Osteogenic proteins |
US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
US20080233170A1 (en) * | 1992-02-21 | 2008-09-25 | Stryker Corporation | Osteogenic Proteins |
ZA9711580B (en) * | 1996-12-25 | 1999-09-23 | Hoechst Marion Roussel Ltd | Process for the production of purified dimeric bone morphogenetic factors. |
HU226554B1 (en) * | 1997-01-30 | 2009-03-30 | Bioph Biotech Entw Pharm Gmbh | Freeze-dried composition of bone morphogenetic protein human mp52 |
WO1998034655A1 (en) † | 1997-02-07 | 1998-08-13 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
EP1863850B1 (en) * | 2005-03-30 | 2009-09-23 | Jung Moon Kim | Non-activated polypeptides having a function of tissue regeneration and method for preparing the same |
KR100775958B1 (en) | 2005-03-30 | 2007-11-13 | 김정문 | Non-activated Polypeptides Having a Function of Tissue Regeneration and Method for Preparing the Same |
US20060286144A1 (en) * | 2005-06-17 | 2006-12-21 | Chunlin Yang | Reinforced collagen scaffold |
JP5654730B2 (en) | 2005-11-18 | 2015-01-14 | バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング | Highly active growth factor variant |
EP1880731A1 (en) * | 2006-07-18 | 2008-01-23 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Human growth and differentiation factor GDF-5 |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
WO2008089987A1 (en) * | 2007-01-25 | 2008-07-31 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of gdf-5 for the improvement or maintenance of dermal appearance |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
EP2019117A1 (en) | 2007-07-27 | 2009-01-28 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Optimized purification process of recombinant growth factor protein |
CN101801405A (en) | 2007-08-07 | 2010-08-11 | 先进科技及再生医学有限责任公司 | Be contained in the protein formulations of the GDF-5 in the acidic aqueous solution |
JP2009106163A (en) * | 2007-10-26 | 2009-05-21 | Kyushu Univ | Nucleic acid sequence, vector, transformant, production method, and nucleic acid sequence primer |
EP2276458A1 (en) | 2008-04-14 | 2011-01-26 | Advanced Technologies and Regenerative Medicine, LLC | Liquid buffered gdf-5 formulations |
US9226898B1 (en) * | 2009-11-18 | 2016-01-05 | Richard C. K. Yen | Submicron particles for the treatment of radiation damage in patients |
US11260110B2 (en) | 2009-11-18 | 2022-03-01 | Ptlnv, Llc, Series Four (4) | Nanoparticles for the therapeutic treatment of radiation-induced skin ulcers |
CA2806143A1 (en) | 2010-07-30 | 2012-02-02 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H | Drug delivery devices and growth factor formulations for accelerated wound healing |
US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
EP2537538A1 (en) | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
EP2602264A1 (en) | 2011-12-05 | 2013-06-12 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | GDF-5 mutant for inducing cartilage formation |
US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
EP4076502A1 (en) | 2019-12-18 | 2022-10-26 | Merck Patent GmbH | Use of the gdf-5 mutant for the treatment of pain and cartilage destruction |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725234A (en) * | 1985-08-15 | 1988-02-16 | Ethridge Edwin C | Alveolar bone grafting process with controlled surface active ceramics |
US5079352A (en) * | 1986-08-22 | 1992-01-07 | Cetus Corporation | Purified thermostable enzyme |
US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5143829A (en) * | 1990-03-29 | 1992-09-01 | California Biotechnology Inc. | High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
DE69233022T2 (en) | 1991-11-04 | 2004-02-12 | Genetics Institute, LLC, Cambridge | RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE |
UA48105C2 (en) * | 1992-02-12 | 2002-08-15 | Біофарм Гезельшафт Цур Біотехнологішен Ентвіклунг Вон Фармака Мбх | DNA FRAGMENT CODING THE PROTEIN OF THE FAMILY TGF-в (VERSIONS), RECOMBINANT DNA MOLECULE (VERSIONS), CELL-HOST (VERSIONS), METHOD FOR OBTAINING THE PROTEIN OF THE FAMILY TGF-в (VERSIONS), PHARMACEUTICAL COMPOSITION (VERSIONS), ANTIBODY OR AN ANTIBODY FRAGMENT (VERSIONS), CDNA MOLECULE (VERSIONS) |
WO1994015949A1 (en) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-5 |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
US6248554B1 (en) | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
CA2176942C (en) * | 1993-12-07 | 2011-11-01 | Anthony J. Celeste | Bmp-12, bmp-13 and tendon-inducing compositions thereof |
US5707962A (en) * | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
-
1996
- 1996-04-19 US US08/945,459 patent/US7235527B2/en not_active Expired - Fee Related
- 1996-04-19 DE DE69636728A patent/DE69636728D1/en not_active Expired - Lifetime
- 1996-04-19 EA EA199700329A patent/EA000582B1/en not_active IP Right Cessation
- 1996-04-19 PL PL96322945A patent/PL186518B1/en not_active IP Right Cessation
- 1996-04-19 PT PT96910198T patent/PT955313E/en unknown
- 1996-04-19 NZ NZ305472A patent/NZ305472A/en not_active IP Right Cessation
- 1996-04-19 WO PCT/JP1996/001062 patent/WO1996033215A1/en active IP Right Grant
- 1996-04-19 ES ES96910198T patent/ES2258774T3/en not_active Expired - Lifetime
- 1996-04-19 DK DK96910198T patent/DK0955313T3/en active
- 1996-04-19 BR BR9608019-1A patent/BR9608019A/en not_active IP Right Cessation
- 1996-04-19 DE DE69636728T patent/DE69636728T4/en not_active Expired - Lifetime
- 1996-04-19 CA CA002216741A patent/CA2216741C/en not_active Expired - Fee Related
- 1996-04-19 HU HU9801697A patent/HU225424B1/en not_active IP Right Cessation
- 1996-04-19 UA UA97115563A patent/UA46767C2/en unknown
- 1996-04-19 AU AU53470/96A patent/AU704515C/en not_active Ceased
- 1996-04-19 EP EP96910198A patent/EP0955313B1/en not_active Expired - Lifetime
- 1996-04-19 AT AT96910198T patent/ATE325131T1/en active
-
1997
- 1997-10-17 OA OA70112A patent/OA10528A/en unknown
- 1997-10-17 NO NO19974812A patent/NO321153B1/en not_active IP Right Cessation
-
2003
- 2003-02-12 US US10/365,231 patent/US7268114B2/en not_active Expired - Fee Related
-
2007
- 2007-08-03 US US11/833,653 patent/US7816103B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2216741A1 (en) | A novel protein and process for preparing the same | |
US5464939A (en) | Highly purified protein, production and use thereof | |
US6534288B1 (en) | C peptide for improved preparation of insulin and insulin analogs | |
FI106029B (en) | Enhanced activation of recombinant DNA proteins | |
JP2001520886A5 (en) | ||
WO1995021919A3 (en) | Protein having tpo activity | |
KR930003515B1 (en) | Method for preparation of human relaxin coding gene | |
JPS63251095A (en) | Novel fused protein and purification thereof | |
IE59488B1 (en) | Eukaryotic fusion proteins, the preparation and use there of, and means for carrying out the process | |
WO1997044356A3 (en) | Ret ligand (retl) for stimulating neural and renal growth | |
HUT43629A (en) | Process for producing fusion proteins | |
Wingender et al. | Expression of human parathyroid hormone in Escherichia coli | |
GB8727045D0 (en) | Immunoglobulin e competitor | |
NZ215598A (en) | Production of epidermal growth factor using recombinant techniques | |
CA2096532C (en) | New human recombinant gamma-interferon | |
JPS6299399A (en) | Biological derivative of human gamma-interferon | |
WO1990004035A1 (en) | Recombinant pdgf and methods for production | |
CN1131313C (en) | Promoters for gene expression | |
Hochuli | Large-scale recovery of interferon alpha-2 a synthesized in bacteria. | |
KR900700615A (en) | Method for preparing human neutrophil chemotactic factor polypeptide | |
CA1273591A (en) | Production of protein | |
EP0327360B1 (en) | Novel polypeptides and DNA encoding said polypeptides | |
CN113969285B (en) | Recombinant expressed sheep interferon-tau BB8 gene and preparation method thereof | |
Pechenov et al. | Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-γ with higher stability and activity | |
US5210029A (en) | Method of producing interleukin-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140422 |